The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

MEDSIR, a leading company dedicated to promoting independent clinical research in oncology internationally and part of ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma.